Literature DB >> 20926779

Thyroid hormone inhibits ERK phosphorylation in pressure overload-induced hypertrophied mouse hearts through a receptor-mediated mechanism.

Jorge Suarez1, Brian T Scott, Jorge A Suarez-Ramirez, Citlalic V Chavira, Wolfgang H Dillmann.   

Abstract

Pressure overload-induced cardiac hypertrophy results in a pathological type of hypertrophy with activation of signaling cascades like the extracellular signal-regulated kinase (ERK) pathway, which promotes negative cardiac remodeling and decreased contractile function. In contrast, thyroid hormone mediates a physiological type of hypertrophy resulting in enhanced contractile function. In addition, thyroid hormone action is diminished in pressure overload-induced cardiac hypertrophy. We hypothesized that thyroid hormone status modulates ERK activity and that administration of thyroid hormone could alter the activity of this kinase in cardiac hypertrophy induced by pressure overload. ERK is activated by phosphorylation; accordingly, we investigated phosphorylation of ERK in hearts of control, hypothyroid, and hyperthyroid mice. In addition, the effect of T3 treatment on ERK phosphorylation in hypertrophied hearts from transverse aortic-constricted (TAC) mice was investigated. Results showed that phosphorylated ERK (p-ERK) was decreased by 25% in hyperthyroid mice. In contrast, hypothyroid mice presented increased p-ERK by 80%. TAC mice presented a greater than fourfold increase of p-ERK compared with control mice. Interestingly, T3 administration dramatically canceled TAC-induced ERK phosphorylation (36% lower compared with control). Raf-1 is upstream of the ERK pathway. TAC mice presented a 45% increase in phospho-Raf-1 (Ser338). T3 treatment inhibited this effect of pressure overload and further decreased p-Raf-1 (Ser338) by 37%, compared with control. Overexpression of thyroid hormone receptor-α in cultured cardiomyocytes potentiated the inhibitory effect of T3 on ERK phosphorylation. We concluded that thyroid hormone has an inhibitory effect on the Raf-1/ERK pathway. Furthermore, treatment of TAC mice with T3 inhibited Raf-1/ERK pathway by a thyroid hormone receptor-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926779      PMCID: PMC3006330          DOI: 10.1152/ajpcell.00168.2010

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  31 in total

1.  Phosphorylation and regulation of Raf by Akt (protein kinase B).

Authors:  S Zimmermann; K Moelling
Journal:  Science       Date:  1999-11-26       Impact factor: 47.728

2.  Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor alpha or beta.

Authors:  B Gloss; S Trost; W Bluhm; E Swanson; R Clark; R Winkfein; K Janzen; W Giles; O Chassande; J Samarut; W Dillmann
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

Review 3.  Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling.

Authors:  Kristina Lorenz; Joachim P Schmitt; Marie Vidal; Martin J Lohse
Journal:  Int J Biochem Cell Biol       Date:  2009-08-08       Impact factor: 5.085

Review 4.  Thyroid hormone and "cardiac metamorphosis": potential therapeutic implications.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Christodoulos Xinaris; Zoi Papadopoulou-Daifoti; Dennis Cokkinos
Journal:  Pharmacol Ther       Date:  2008-03-20       Impact factor: 12.310

5.  Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study.

Authors:  Alessandro Pingitore; Elena Galli; Andrea Barison; Annalisa Iervasi; Maria Scarlattini; Daniele Nucci; Antonio L'abbate; Rita Mariotti; Giorgio Iervasi
Journal:  J Clin Endocrinol Metab       Date:  2008-01-02       Impact factor: 5.958

6.  Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo.

Authors:  Nicole H Purcell; Benjamin J Wilkins; Allen York; Marc K Saba-El-Leil; Sylvain Meloche; Jeffrey Robbins; Jeffery D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-20       Impact factor: 11.205

7.  Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure.

Authors:  Kyle K Henderson; Sara Danzi; Jennifer T Paul; Greg Leya; Irwin Klein; Allen M Samarel
Journal:  Circ Heart Fail       Date:  2009-03-25       Impact factor: 8.790

Review 8.  Mini-review: Cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells.

Authors:  Paul J Davis; Min Zhou; Faith B Davis; Larry Lansing; Shaker A Mousa; Hung-Yun Lin
Journal:  Physiol Behav       Date:  2009-02-25

Review 9.  MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets.

Authors:  Anthony J Muslin
Journal:  Clin Sci (Lond)       Date:  2008-10       Impact factor: 6.124

Review 10.  Cardiac hypertrophy and thyroid hormone signaling.

Authors:  Wolfgang Dillmann
Journal:  Heart Fail Rev       Date:  2009-01-06       Impact factor: 4.214

View more
  13 in total

1.  Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK signalings.

Authors:  Iordanis Mourouzis; Polixeni Mantzouratou; Georgios Galanopoulos; Erietta Kostakou; Nikolaos Roukounakis; Alexandros D Kokkinos; Dennis V Cokkinos; Constantinos Pantos
Journal:  Mol Cell Biochem       Date:  2011-12-02       Impact factor: 3.396

2.  In vivo selective expression of thyroid hormone receptor α1 in endothelial cells attenuates myocardial injury in experimental myocardial infarction in mice.

Authors:  Jorge Suarez; Hong Wang; Brian T Scott; Haiyun Ling; Ayako Makino; Eric Swanson; Joan Heller Brown; Jorge A Suarez; Shera Feinstein; Julieta Diaz-Juarez; Wolfgang H Dillmann
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-05-21       Impact factor: 3.619

Review 3.  Thyroid hormone receptors and resistance to thyroid hormone disorders.

Authors:  Tânia M Ortiga-Carvalho; Aniket R Sidhaye; Fredric E Wondisford
Journal:  Nat Rev Endocrinol       Date:  2014-08-19       Impact factor: 43.330

4.  Ezh2 promotes TRβ lysine methylation-mediated degradation in hepatocellular carcinoma.

Authors:  Su Chan Park; Ji Min Lee
Journal:  Genes Genomics       Date:  2021-12-01       Impact factor: 1.839

5.  Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.

Authors:  Dotan Moskovich; Yael Finkelshtein; Adi Alfandari; Amit Rosemarin; Tzuri Lifschytz; Avivit Weisz; Santanu Mondal; Harinarayana Ungati; Aviva Katzav; Debora Kidron; Govindasamy Mugesh; Martin Ellis; Bernard Lerer; Osnat Ashur-Fabian
Journal:  Oncogene       Date:  2021-09-23       Impact factor: 9.867

6.  Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice.

Authors:  Iordanis Mourouzis; Erietta Kostakou; Georgios Galanopoulos; Polixeni Mantzouratou; Constantinos Pantos
Journal:  Mol Cell Biochem       Date:  2013-03-27       Impact factor: 3.396

Review 7.  Small and large animal models in cardiac contraction research: advantages and disadvantages.

Authors:  Nima Milani-Nejad; Paul M L Janssen
Journal:  Pharmacol Ther       Date:  2013-10-15       Impact factor: 12.310

8.  Ablation of ALCAT1 mitigates hypertrophic cardiomyopathy through effects on oxidative stress and mitophagy.

Authors:  Xiaolei Liu; Benlan Ye; Shane Miller; Huijuan Yuan; Hongxiu Zhang; Liang Tian; Jia Nie; Rieko Imae; Hiroyuki Arai; Yuanjian Li; Zeneng Cheng; Yuguang Shi
Journal:  Mol Cell Biol       Date:  2012-09-04       Impact factor: 4.272

9.  American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models.

Authors:  Antonio C Bianco; Grant Anderson; Douglas Forrest; Valerie Anne Galton; Balázs Gereben; Brian W Kim; Peter A Kopp; Xiao Hui Liao; Maria Jesus Obregon; Robin P Peeters; Samuel Refetoff; David S Sharlin; Warner S Simonides; Roy E Weiss; Graham R Williams
Journal:  Thyroid       Date:  2013-12-12       Impact factor: 6.568

10.  Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology.

Authors:  Sibel Ertek; Arrigo F Cicero
Journal:  Arch Med Sci       Date:  2013-11-05       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.